Document is current
Any future updates will be listed below
-
Authors
Daly, Adrian F. http://orcid.org/0000-0001-6130-2975
Dunnington, Leslie A.
Rodriguez-Buritica, David F.
Spiegel, Erica
Brancati, Francesco http://orcid.org/0000-0003-3624-2354
Mantovani, Giovanna
Rawal, Vandana M.
Faucz, Fabio Rueda
Hijazi, Hadia
Caberg, Jean-Hubert
Nardone, Anna Maria
Bengala, Mario
Fortugno, Paola
Del Sindaco, Giulia
Ragonese, Marta
Gould, Helen
Cannavò, Salvatore
Pétrossians, Patrick
Lania, Andrea
Lupski, James R. http://orcid.org/0000-0001-9907-9246
Beckers, Albert
Stratakis, Constantine A.
Levy, Brynn
Trivellin, Giampaolo http://orcid.org/0000-0003-2384-4153
Franke, Martin http://orcid.org/0000-0002-4626-3290
-
Funding
Funding for this research was provided by:
Fondazione Telethon (GGP20130)
Society for Endocrinology
Centre Hospitalier Universitaire de Liège (2018/20)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z1A HD008920)
National Institute of Health (R35NS105078)
Ministero della Salute (Ricerca Corrente", T3-AN-14 “LifeMap”)
Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN PNRR 2022, PRIN 2022)
'la Caixa' Foundation (100010434, fellowship code LCF/BQ/PR22/11920006)
- License Information
-
More Information
Article History
Received: 16 May 2024
Accepted: 23 August 2024
First Online: 13 September 2024
Declarations
:
: The study conformed to the principles of the Helsinki Declaration. Subjects were recruited under the University of Liège Ethics committee approved protocol B707201420418; or under the <i>Eunice Kennedy Shriver</i> National Institute of Child Health and Human Development, National Institutes of Health protocol 97-CH-0076 (see ClinicalTrials.gov: NCT00001595 for details), or under Project code PGR00919 of the University of L’Aquila Internal Review Board. The Institutional Review Boards of all Centers approved the study, and written informed consent was obtained from all the subjects/guardians.
: Written consent to publish patient-related details was obtained for all subjects.
: AFD, FRF, AB, CAS, and GT hold a patent on GPR101 and its function (US Patent No. 10,350,273, Treatment of Hormonal Disorders of Growth). JRL has stock ownership in 23andMe and is a paid consultant for Genome International. CAS is co-founder and Director of ASTREA, a precision medicine company. The authors declare no other competing interests.
